Scientists in the U.K. have secured funding for a clinical trial that will test whether multiple drugs used to treat…
Articles by Marisa Wexler, MS
Over the coming weeks, Matter of Time — a documentary that chronicles how scientists and advocates are working to find…
International Epidermolysis Bullosa Awareness Week is the last week of October — this year it’s Oct. 25-31 — and the…
The U.S. Food and Drug Administration (FDA) approved an update to the prescribing information of Vyjuvek (beremagene geperpavec), a…
A new six-minute film called “Living Between Pain and Hope” spotlights the impact that living with epidermolysis bullosa…
Lucile Packard Children’s Hospital Stanford, a medical facility in the San Francisco Bay Area, has completed the requirements needed to…
Note: This story was updated June 18, 2025, to correct the source of the analysis of Phase 3 trial data.
The U.S. Food and Drug Administration (FDA) has approved the cell-based gene therapy prademagene zamikeracel, previously pz-cel or EB-101, for…
Note: This story was updated April 3, 2025, to correct that enrollment criteria in Europe differs from criteria at other…
Castle Creek Biosciences has secured $75 million in financing to support a Phase 3 trial testing its gene therapy to…
France-based pharma company Theravia has obtained rights to an experimental molecule that may be used to treat epidermolysis…
The U.S. Food and Drug Administration (FDA) is expected to decide whether or not to approve the cell therapy…